ATE406355T1 - Valsartan salze - Google Patents

Valsartan salze

Info

Publication number: ATE406355T1
Authority: AT; Austria
Prior art keywords: valsartan; salts; valsartan salts
Prior art date: 2000-07-19

Application number

AT01969407T

Other languages

English (en)

Inventor

Erwin Marti

Hans Oswald

Peter Buehlmayer

Wolfgang Marterer

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-19

Filing date

2001-07-17

Publication date

2008-09-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406355(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-17 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406355T1 publication Critical patent/ATE406355T1/de

Links

SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AT01969407T 2000-07-19 2001-07-17 Valsartan salze ATE406355T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00115556		2000-07-19

Publications (1)

Publication Number	Publication Date
ATE406355T1 true ATE406355T1 (de)	2008-09-15

Family

ID=8169294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01969407T ATE406355T1 (de)	2000-07-19	2001-07-17	Valsartan salze

Country Status (30)

Country	Link
US (5)	US20030207930A1 (de)
EP (1)	EP1313714B1 (de)
JP (1)	JP4102664B2 (de)
KR (1)	KR100529658B1 (de)
CN (2)	CN1216873C (de)
AR (2)	AR032758A1 (de)
AT (1)	ATE406355T1 (de)
AU (2)	AU2001289672B2 (de)
BR (1)	BR0112665A (de)
CA (1)	CA2415962C (de)
CY (1)	CY1108559T1 (de)
CZ (1)	CZ303389B6 (de)
DE (1)	DE60135560D1 (de)
DK (1)	DK1313714T3 (de)
EC (1)	ECSP034436A (de)
ES (1)	ES2309090T3 (de)
HU (1)	HU229280B1 (de)
IL (2)	IL153882A0 (de)
MX (1)	MXPA03000525A (de)
MY (2)	MY152846A (de)
NO (1)	NO326504B1 (de)
NZ (1)	NZ523557A (de)
PE (1)	PE20020613A1 (de)
PL (1)	PL205715B1 (de)
PT (1)	PT1313714E (de)
RU (1)	RU2275363C2 (de)
SI (1)	SI1313714T1 (de)
SK (1)	SK287558B6 (de)
WO (1)	WO2002006253A1 (de)
ZA (1)	ZA200300285B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1313714T3 (da)	2000-07-19	2008-12-15	Novartis Ag	Valsartansalte
CA2472399C (en) *	2002-01-17	2012-02-21	Novartis Ag	Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en)	2002-01-17	2008-12-23	Novartis Ag	Methods of treatment and pharmaceutical composition
US6869970B2 (en)	2002-02-04	2005-03-22	Novartis Ag	Crystalline salt forms of valsartan
AU2003223637A1 (en) *	2002-04-15	2003-11-03	Dr. Reddy's Laboratories Limited	Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
KR20050000556A (ko) *	2002-05-17	2005-01-05	노파르티스 아게	심근 경색증의 속발 예방을 위한 안지오텐신 ｉｉ 수용체차단제 및 베타-차단제의 조합물
CA2486557A1 (en) *	2002-06-13	2003-12-24	Novartis Ag	Calcium salts of indole derived statins
GB0222056D0 (en) *	2002-09-23	2002-10-30	Novartis Ag	Process for the manufacture of organic compounds
EP1950204A1 (de)	2003-03-17	2008-07-30	Teva Pharmaceutical Industries Ltd.	Amorphe Form von Valsartan
WO2004083192A1 (en) *	2003-03-17	2004-09-30	Teva Pharmaceutical Industries Ltd.	Polymorphis of valsartan
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
US20050165075A1 (en) *	2003-03-31	2005-07-28	Hetero Drugs Limited	Novel amorphous form of valsartan
TW200505879A (en) *	2003-04-21	2005-02-16	Teva Pharma	Process for the preparation of valsartan
WO2005049587A1 (en) *	2003-11-21	2005-06-02	Ranbaxy Laboratories Limited	Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) *	2004-07-06	2006-01-12	Novartis Ag	Combination of organic compounds
EP1674080A1 (de) *	2004-12-24	2006-06-28	KRKA, D.D., Novo Mesto	Feste pharmazeutische Zusammensetzung valsartan enthaltend
AU2005318365B2 (en) *	2004-12-24	2011-02-03	Krka, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) *	2005-02-14	2005-03-23	Novartis Ag	Combination of organic compounds
WO2007017897A2 (en) *	2005-05-25	2007-02-15	Ipca Laboratories Ltd.	Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr)	2005-06-06	2008-05-30	Sanofi Aventis Sa	Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) *	2005-10-19	2007-04-26	Novartis Ag	Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2459809C2 (ru) *	2005-11-09	2012-08-27	Новартис Аг	Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007071750A1 (en) *	2005-12-22	2007-06-28	Enantia, S.L.	Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) *	2006-06-23	2008-03-27	Usv Limited	Process for the preparation of micronized valsartan
WO2008018843A1 (en) *	2006-08-08	2008-02-14	Ulkar Kimya Sanayi Ve Ticaret As	Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) *	2006-12-14	2008-06-26	Isp Investments Inc.	Amorphous valsartan and the production thereof
JP2010526126A (ja) *	2007-05-07	2010-07-29	シプラ・リミテッド	バルサルタンの製造方法
DE602007000211D1 (de) *	2007-06-07	2008-12-11	Inke Sa	Verfahren zur Gewinnung eines zur Gewinnung von Valsartan nützlichen Valsartan-Salzes
CN104119336B (zh) *	2007-10-05	2016-08-24	维拉斯通股份有限公司	嘧啶取代的嘌呤衍生物
PL2295035T3 (pl)	2007-11-06	2016-11-30		Podwójne działanie kompozycji farmaceutycznych opartych na superstrukturach antagonisty/blokera receptora angiotensyny (arb) oraz inhibitora obojętnej endopeptydazy (nep)
WO2009064681A2 (en)	2007-11-12	2009-05-22	Novartis Ag	Liquid compositions comprising valsartan
BR112013002589A2 (pt)	2010-08-03	2019-09-24	Novartis Ag	valsatana altamente cristalina
WO2012056294A1 (en)	2010-10-29	2012-05-03	Jubilant Life Sciences Ltd.	An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
JP5981940B2 (ja) *	2011-01-20	2016-08-31	ジエンスハンセンファーマセウティカルカンパニーリミテッド	アジルサルタン有機アミン塩、その製造方法及び使用
US9006462B2 (en)	2013-02-28	2015-04-14	Dermira, Inc.	Glycopyrrolate salts
US8558008B2 (en)	2013-02-28	2013-10-15	Dermira, Inc.	Crystalline glycopyrrolate tosylate
KR20150119468A (ko)	2013-02-28	2015-10-23	더미라, 인코포레이티드	글리코피롤레이트 염
WO2017012600A1 (en)	2015-07-20	2017-01-26	Zentiva, K.S.	A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) *	2015-09-07	2017-03-16	Sun Pharmaceutical Industries Limited	Solid forms of valsartan and sacubitril
CN105541741A (zh) *	2016-01-14	2016-05-04	青岛友诚高新技术有限公司	一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) *	2016-07-29	2016-12-21	陈欣怡	一种缬沙坦的新型固体形式
WO2018040065A1 (zh) *	2016-09-02	2018-03-08	诺瑞特国际药业股份有限公司	缬沙坦二钠盐的晶型
TWI648267B (zh) *	2016-09-02	2019-01-21	諾瑞特國際藥業股份有限公司	纈沙坦二鈉鹽新晶型
JP7022747B2 (ja)	2016-10-28	2022-02-18	バイオコン・リミテッド	アモルファスサクビトリルバルサルタン三ナトリウムおよびその調製のためのプロセス
WO2018178295A1 (en)	2017-03-31	2018-10-04	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Stable hot-melt extrudate containing valsartan and sacubitril
WO2019008485A1 (en) *	2017-07-06	2019-01-10	Mankind Pharma Ltd	FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
MX391562B (es)	2017-07-28	2025-03-21	Synthon Bv	Composicion farmaceutica que comprende sacubitril y valsartan
US20200276129A1 (en)	2017-10-13	2020-09-03	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Tablet containing valsartan and sacubitril
EP3498698A1 (de)	2017-12-15	2019-06-19	Mankind Pharma Ltd	Festformen von valsartandinatrium und verfahren zur herstellung davon
CN108794418A (zh) *	2018-09-18	2018-11-13	中国药科大学	一种缬沙坦烟酰胺共无定形物
EP3766484B1 (de)	2019-07-19	2021-08-25	Zentiva, K.S.	Feste pharmazeutische darreichungsform mit valsartan und sakubitril
WO2021111464A1 (en) *	2019-12-02	2021-06-10	Harman Finochem Limited	A process for the preparation of highly pure valsartan

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4499017A (en) *	1983-06-06	1985-02-12	Pfizer Inc.	Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
US4820843A (en) *	1987-05-22	1989-04-11	E. I. Du Pont De Nemours And Company	Tetrazole intermediates to antihypertensive compounds
ATE134624T1 (de) *	1990-02-19	1996-03-15	Ciba Geigy Ag	Acylverbindungen
JPH05105698A (ja) *	1991-06-13	1993-04-27	Takeda Chem Ind Ltd	ホスホン酸誘導体、その製造法および用途
BR9507086A (pt)	1994-03-17	1997-09-16	Ciba Geigy Ag	Tratamento de nefroterapia diabética com valsartan
FR2725987B1 (fr) *	1994-10-19	1997-01-10	Sanofi Sa	Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
AU5399096A (en)	1995-04-07	1996-10-23	Novartis Ag	Combination compositions containing benazepril or benazeprilat and valsartan
DE69624253T2 (de) *	1995-10-06	2003-08-07	Novartis Ag, Basel	Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
GT199800126A (es)	1997-08-29	2000-01-29		Terapia de combinacion.
IT1301759B1 (it) *	1998-06-19	2000-07-07	Nicox Sa	Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) *	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DK1313714T3 (da)	2000-07-19	2008-12-15	Novartis Ag	Valsartansalte

2001
- 2001-07-17 DK DK01969407T patent/DK1313714T3/da active
- 2001-07-17 AR ARP010103417A patent/AR032758A1/es not_active Application Discontinuation
- 2001-07-17 AU AU2001289672A patent/AU2001289672B2/en not_active Ceased
- 2001-07-17 SI SI200130881T patent/SI1313714T1/sl unknown
- 2001-07-17 CA CA2415962A patent/CA2415962C/en not_active Expired - Fee Related
- 2001-07-17 EP EP01969407A patent/EP1313714B1/de not_active Expired - Lifetime
- 2001-07-17 ES ES01969407T patent/ES2309090T3/es not_active Expired - Lifetime
- 2001-07-17 US US10/333,100 patent/US20030207930A1/en not_active Abandoned
- 2001-07-17 WO PCT/EP2001/008253 patent/WO2002006253A1/en not_active Ceased
- 2001-07-17 AU AU8967201A patent/AU8967201A/xx active Pending
- 2001-07-17 HU HU0300731A patent/HU229280B1/hu not_active IP Right Cessation
- 2001-07-17 KR KR10-2003-7000815A patent/KR100529658B1/ko not_active Expired - Fee Related
- 2001-07-17 CN CN018130399A patent/CN1216873C/zh not_active Expired - Lifetime
- 2001-07-17 AT AT01969407T patent/ATE406355T1/de active
- 2001-07-17 CZ CZ20030117A patent/CZ303389B6/cs not_active IP Right Cessation
- 2001-07-17 DE DE60135560T patent/DE60135560D1/de not_active Expired - Lifetime
- 2001-07-17 PE PE2001000723A patent/PE20020613A1/es not_active Application Discontinuation
- 2001-07-17 MX MXPA03000525A patent/MXPA03000525A/es active IP Right Grant
- 2001-07-17 RU RU2003104789/04A patent/RU2275363C2/ru not_active IP Right Cessation
- 2001-07-17 PL PL360737A patent/PL205715B1/pl not_active IP Right Cessation
- 2001-07-17 PT PT01969407T patent/PT1313714E/pt unknown
- 2001-07-17 SK SK55-2003A patent/SK287558B6/sk not_active IP Right Cessation
- 2001-07-17 IL IL15388201A patent/IL153882A0/xx unknown
- 2001-07-17 JP JP2002512157A patent/JP4102664B2/ja not_active Expired - Fee Related
- 2001-07-17 NZ NZ52355701A patent/NZ523557A/xx not_active IP Right Cessation
- 2001-07-17 CN CNB2005100077076A patent/CN100413852C/zh not_active Expired - Lifetime
- 2001-07-17 MY MYPI20064483 patent/MY152846A/en unknown
- 2001-07-17 MY MYPI20013368A patent/MY136446A/en unknown
- 2001-07-17 BR BR0112665-2A patent/BR0112665A/pt not_active IP Right Cessation
2003
- 2003-01-09 IL IL153882A patent/IL153882A/en active IP Right Grant
- 2003-01-10 ZA ZA200300285A patent/ZA200300285B/en unknown
- 2003-01-17 EC EC2003004436A patent/ECSP034436A/es unknown
- 2003-01-17 NO NO20030232A patent/NO326504B1/no not_active IP Right Cessation
2007
- 2007-02-23 US US11/678,284 patent/US20070149587A1/en not_active Abandoned
2008
- 2008-08-05 US US12/186,172 patent/US8278339B2/en not_active Expired - Lifetime
- 2008-10-27 CY CY20081101215T patent/CY1108559T1/el unknown
- 2008-11-19 AR ARP080105034A patent/AR069374A2/es not_active Application Discontinuation
2012
- 2012-08-30 US US13/599,032 patent/US20120329844A1/en not_active Abandoned
2013
- 2013-11-15 US US14/081,441 patent/US9499499B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20070149587A1 (en)	2007-06-28
EP1313714A1 (de)	2003-05-28
CA2415962C (en)	2010-07-06
NZ523557A (en)	2004-12-24
IL153882A (en)	2009-09-01
ES2309090T3 (es)	2008-12-16
HUP0300731A3 (en)	2006-05-29
CA2415962A1 (en)	2002-01-24
US9499499B2 (en)	2016-11-22
HUP0300731A2 (hu)	2003-09-29
NO20030232D0 (no)	2003-01-17
PL360737A1 (en)	2004-09-20
RU2275363C2 (ru)	2006-04-27
ZA200300285B (en)	2004-03-25
ECSP034436A (es)	2003-03-10
MY152846A (en)	2014-11-28
BR0112665A (pt)	2003-06-24
CN1443176A (zh)	2003-09-17
MXPA03000525A (es)	2003-05-14
CN100413852C (zh)	2008-08-27
DK1313714T3 (da)	2008-12-15
US20120329844A1 (en)	2012-12-27
US20140073677A1 (en)	2014-03-13
PE20020613A1 (es)	2002-08-07
KR100529658B1 (ko)	2005-11-21
SK287558B6 (sk)	2011-02-04
SK552003A3 (en)	2003-07-01
DE60135560D1 (de)	2008-10-09
US8278339B2 (en)	2012-10-02
CZ2003117A3 (cs)	2003-05-14
CY1108559T1 (el)	2014-04-09
HK1055963A1 (en)	2004-01-30
CN1680341A (zh)	2005-10-12
IL153882A0 (en)	2003-07-31
CZ303389B6 (cs)	2012-08-29
HU229280B1 (en)	2013-10-28
NO326504B1 (no)	2008-12-15
EP1313714B1 (de)	2008-08-27
JP2004504307A (ja)	2004-02-12
AR032758A1 (es)	2003-11-26
MY136446A (en)	2008-10-31
US20080293791A1 (en)	2008-11-27
PL205715B1 (pl)	2010-05-31
SI1313714T1 (sl)	2009-02-28
AU8967201A (en)	2002-01-30
PT1313714E (pt)	2008-11-03
WO2002006253A1 (en)	2002-01-24
KR20030015888A (ko)	2003-02-25
AU2001289672B2 (en)	2005-12-08
AR069374A2 (es)	2010-01-20
NO20030232L (no)	2003-01-17
US20030207930A1 (en)	2003-11-06
CN1216873C (zh)	2005-08-31
JP4102664B2 (ja)	2008-06-18

Legal Events

Date

Code

Title

Description

2009-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1313714

Country of ref document: EP

Publication	Publication Date	Title
ATE406355T1 (de)	2008-09-15	Valsartan salze
NO20026196L (no)	2003-02-24	Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da)	2010-03-29	Arylkondeserede azapolycykliske forbindelser
DK1292604T3 (da)	2009-06-15	2-Aminocarbonyl-9H-purinderivater
DZ3409A1 (fr)	2002-02-21	Association therapeuthique
ATE307121T1 (de)	2005-11-15	Substituierte arylpyrazine
ATE288437T1 (de)	2005-02-15	Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
AR028393A1 (es)	2003-05-07	Iminoazidas substituidas
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DE60138221D1 (de)	2009-05-14	Bandspule
ATE332895T1 (de)	2006-08-15	Tetrazolderivate
ID29755A (id)	2001-10-11	Senyawa-senyawa organosilikon
AR028302A1 (es)	2003-05-07	Feniluracilos substituidos
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
ATE372338T1 (de)	2007-09-15	Deshalogenverbindungen
NO20030303D0 (no)	2003-01-20	Kalsilytiske forbindelser
ATE366244T1 (de)	2007-07-15	Tetrazolderivate
NO20023508D0 (no)	2002-07-23	Kalsilyttiske forbindelser
NO20031837L (no)	2003-06-20	Kalsilytiske forbindelser
DK1246791T3 (da)	2005-02-14	Aminomethyl-phenyl-cyklohexanonderivater
TR200100070A3 (tr)	2001-08-21	Bilesim
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater
ES1046338Y (es)	2001-06-01	Salero pefeccionado